经尿道气化电切治疗前列腺增生

目的 探讨经尿道气化电切术(TUVP)治疗前列腺增生(BPH)的安全性和有效性.方法 对161例前列腺增生患者行TUVP治疗,其中伴全身症状和泌尿系并发症2种以上的高危患者、前列腺重量＞50g的患者共68例.平均年龄72.5岁,经围手术期处理后行TUVP治疗.结果 所有患者均安全度过围手术期.随访3～24个月,平均IPSS从26.6下降至6.6、MFR从6.2ml/s上升到18.6ml/s、PVR从376ml下降到8.9ml.结论 TUVP治疗BPH以及高危重度BPH是安全有效的,强调术中对前列腺尖部采用电切治疗以避免术后尿失禁等并发症的发生.     

小切口胆囊切除术中胆道损伤的预防

目的探讨预防小切口胆囊切除术（MC）中胆道损伤的方法。方法对本组15131例MC中发生的18例胆道损伤进行回顾分析。结果1994年12月前施行MC2321例，发生胆道损伤9例（0．39％），1995年以来实施MC12810例，发生胆道损伤9例（0．07％）。结论思想上高度重视、规范手术适应证、规范手术操作是预防MC中胆道损伤的关键。     

放线菌素23-21对裸小鼠人鼻咽癌细胞系移植瘤和人胃癌细胞系移植瘤的抑制作用

放线菌素23-21属放线菌素类抗癌抗生素,由浅黄色链霉菌产生,该菌从中国福州土壤样品中分离得到。采用裸小鼠人鼻咽癌细胞系(CNE-2Z)和人胃癌细胞系(MGc-803)两种移植模型观察了放线菌素23-21的作用。放线菌素23—21 50μg/kg,对CNE-27移植瘤和MGc803移植瘤的抑制率分别为58.4%(P<0.05)和68.7%(P<0.05)。肿瘤生长曲线显示,治疗组肿瘤生长缓慢。电镜检查,治疗组瘤细胞可见核仁分离和微球体形成。提示放线菌素23-21可能有抑制核仁rRNA合成的作用。在有效剂量下,未见重要脏器病理改变。     

软骨细胞诱导骨髓基质干细胞构建带内支撑的组织工程化软骨

目的 探讨以聚羟基乙酸(PGA)包裹特定形态的医用假体材料--多孔高密度聚乙烯(HDPE,商品名为MEDPOR)为支架,应用软骨细胞诱导骨髓基质干细胞(BMSCs),共培养构建特定形态的带内支撑组织工程化软骨医用假体的可能性.方法 以直径3 mm、长5 mm的圆柱形HDPE,外裹 1 mm厚PGA为支架,将体外分别培养的新生猪BMSCs和耳郭软骨细胞按7∶3混合,以10×10 7/ml细胞浓度接种于支架上,同时以相同浓度的单纯软骨细胞和单纯BMSCs分别接种,作为阳性对照组(PC组)和阴性对照组(NC组).经体外培养2周及在裸鼠皮下移植4、8周后取材 ,行大体观察、组织学、组织化学及免疫组化检测.结果 各组细胞均与材料黏附良好.实验组和阳性对照组均形成了大体形态良好的HDPE-软骨复合体,内支撑的HDPE与外层软骨结合紧密.组织学可见成熟的软骨陷窝结构,软骨渗入HDPE孔隙内部、异染基质及Ⅱ型胶原呈强阳性表达.结论 以HDPE为内支撑,外裹PGA的支架,接种混合细胞,可于皮下构建特定形态、组织学良好的HDPE-软骨复合体.     

老年人脑卒中后抑郁症的发病机制及预防

[目的]探讨脑卒中后老年患者抑郁症的发病机制及预防措施。[方法]归纳相关资料,对命题进行分析。[结论]医护人员应采取针对性的用药及护理措施,预防患者卒中后抑郁症的发生。     

重症急性胰腺炎早期治疗的探讨及分析

目的 探讨重症急性胰腺炎（SAP）早期治疗体会及外科手术治疗时机和手术方式的选择。方法 对比分析1989—1995年以早期手术为主的36例SAP（A组）与1996—2003年7年中非手术治疗为主的44例SAP（B组）的治愈率和死亡率。结果 B组的死亡率明显低于A组，A组的治愈率低于B组。结论 SAP早期的急性炎症反应期，手术只能加重对机体的打击，加重SAP全身炎症反应，增加手术死亡率。故SAP早期治疗应以非手术疗法为主。当内科治疗无效，手术治疗是唯一的选择，而手术时机的掌握和手术方式的选择更为重要，直接影响手术结果。     

根管治疗术远期疗效的影响因素

根管治疗术（root canal therapy,RCT）是治疗牙髓病、根尖周病的主要方法.影响根管治疗术远期疗效的因素较多,而RCT前根尖周状态和根充位置是两大主要因素.     

A drug interaction study between ticlopidine and cyclosporin in heart transplant recipients

Objectives: Previous uncontrolled studies have suggested an interaction between ticlopidine, a major antiplatelet agent, and cyclosporin in heart- and kidney-transplant recipients. The aims of this study were to examine in a randomised, double-blind fashion, the possible interaction between cyclosporin A and ticlopidine (250 mg per day) and the tolerability of this combination in heart-transplant recipients. Methods: Twenty heart-transplant recipients were randomised into either a treated or a placebo group. Blood samples were drawn for time-course evaluation of cyclosporin blood levels over a period of 12 h, following the morning intake of cyclosporin and, for platelet aggregation studies, before and after 14 days of ticlopidine administration. Twenty four-hour urine samples were collected for 6-β-hydroxycortisol measurements, before and after 14 days of ticlopidine. Results: Although given at half the recommended daily dosage, ticlopidine significantly reduced platelet aggregation. Pharmacokinetic parameters indicate that the bioavailability of cyclosporin A was not significantly modified by ticlopidine. However, one patient in the ticlopidine group was withdrawn because of a major fall in cyclosporin blood level within 3 days of treatment. Urinary excretion of 6-β-hydroxycortisol was augmented after treatment in the ticlopidine group compared with the placebo group, suggesting that induction of drug metabolism might have occurred. Data also show quite a large intra-individual variability in cyclosporin bioavailability in the placebo group, suggesting that poor absorption of the drug formulation and/or poor compliance might have contributed to the decreased cyclosporin blood levels in the patient withdrawn from this study and in previous uncontrolled studies. Conclusion: Cyclosporin bioavailability was not clearly modified by a half dosage of ticlopidine in this study. We, however, recommend closely monitoring cyclosporin blood levels when prescribing ticlopidine. Further studies will be needed with new formulations of cyclosporin or when using the full dosage of ticlopidine. Received: 20 July 1996 / Accepted in revised form: 12 February 1997     

HLA-B*27 subtyping by PCR-RFLP in Spanish patients with ankylosing spondyiitis

Abstract: We describe the use of restriction analysis on PCR-amplified DNA for detecting all B*27 subtypes except B*2710 and B*2711 (i.e. from B*2701 to B*2709). After detecting B*27 by Sty I, double digestions consisting of Sty I plus another informative enzyme led to subtype assignment. We used mismatched primers to create restriction sites when necessary. The method avoids group-specific amplifications and other laborious optimization procedures. It was successfully tested on a panel of well characterized cell lines covering different B*27 subtypes. Then, we studied a group of 57 ankylosing spondyiitis patients and 746 controls from the south of Spain. B*27 showed a very strong association with the disease (OR=211.27, P=\0˜7). B*2702 and B*2705 distribution in controls (20% and 77.1%, respectively) differed from previously reported data in the Spanish population. We unexpectedly found the B*2707 allele in our population (one control).     

雌性大鼠、小鼠生殖系统与人子宫内膜甾体激素分泌细胞的研究

对雌性大鼠、小鼠的生殖系统,人的子宫内膜与蜕膜进行了3-β-羟基甾体脱氢酶(3-β-HSDH)和脂类的组织化学研究。结果表明:在大鼠和小鼠的卵巢内,颗粒黄体细胞和膜黄体细胞3-β-HSDH呈强阳性反应,卵泡膜内层细胞与间质细胞呈中等程度阳性反应;大鼠与小鼠子宫内膜的表面上皮与腺上皮呈阳性反应;人早孕期蜕膜中的子宫腺上皮细胞与大蜕膜细胞呈阳性反应:在大鼠与小鼠的输卵中偶尔见到阳性反应物质;在人的子宫内膜中,没有见到阳性反应。本研究证明,雌性大鼠和小鼠除卵巢有分泌甾体素的功能外,子宫也有分泌甾体激素的功能。人早孕期蜕膜组织中的子宫腺与大蜕膜细胞都能分泌甾体激素。